WILLIAMS AND JENSEN, PLLC for PHRMA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. IPI drug pricing proposal, Medicare Rebate Rule. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. H.R. 1425, Patient Protection and Affordable Care Enhancement Act. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
Budget/Appropriations BUD
Issues related to pharmaceutical development; Policies impacting Medicare Part D; Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Buy America procurement proposals. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | COS, Rep Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shrd employee, Ofc of the Speaker & Ofc of VA 7; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Republican Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Roy Blunt; Prof Staff House Committee E&C; SR LA Rep Cox. |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
Health Issues HCR
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. CMMI Medicare Part B Demonstration. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. H.R. 1425, Patient Protection and Affordable Care Enhancement Act. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
Trade (domestic/foreign) TRD
IP Protections related to trade agreements; Issues related to pharmaceutical manufacturing and development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | COS, Rep.Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
Defense DEF
Issues related to pharmaceutical manufacturing and development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | COS, Rep.Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.